The Eversense E3 CGM System is covered by a broad range of payers. Each has its own policy on how to reimburse for both the Eversense E3 CGM system as well as the corresponding …

This study characterized the interference profile of the Eversense CGM System (Senseonics, Inc., Germantown, MD), which has a different mechanism of glucose detection than other …

While factory calibration might be possible for transcutaneous sensors lasting up to 2 weeks, a long-term implantable sensor lasting up to 180 days, essentially 12 times longer, requires …

The Eversense ® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The …

Background: A prior study (PRECISE II) demonstrated that an implantable continuous glucose monitoring (CGM) system (Eversense CGM System) provided accurate glucose readings …

It's important to consider what has happened and what is about to happen when using Eversense E3 CGM to make treatment decisions. Glucose below target at 75 mg/dL but rising …

Background: Real-time continuous glucose monitoring is associated with significant benefits for diabetes management. Implantable sensors could overcome some challenges reportedly …

Ascensia Diabetes Care provides a wide range of devices for Blood Glucose Monitoring & Continuous Glucose Monitoring to help manage diabetes. Learn more.

Discover Ascensia Diabetes Care's range of devices for blood glucose monitoring and continuous glucose monitoring to help your patients manage diabetes.

*Patients need to be registered in GlucoContro.online and approve sharing their data with their healthcare professional ** Ambulatory glucose profile The CONTOUR ® DIABETES app …